دورية أكاديمية
أعرض في EDS

Controlled adsorption of multiple bioactive proteins enables targeted mast cell nanotherapy.

التفاصيل البيبلوغرافية
العنوان: Controlled adsorption of multiple bioactive proteins enables targeted mast cell nanotherapy.
المؤلفون: Du F; Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA., Rische CH; Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA.; Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Li Y; Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, USA., Vincent MP; Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA., Krier-Burris RA; Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Qian Y; Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA., Yuk SA; Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA., Almunif S; Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA., Bochner BS; Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Qiao B; Department of Materials Science and Engineering, Northwestern University, Evanston, IL, USA.; Department of Natural Sciences, Baruch College, City University of New York, New York, NY, USA., Scott EA; Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA. evan.scott@northwestern.edu.; Simpson Querrey Institute, Northwestern University, Chicago, IL, USA. evan.scott@northwestern.edu.; Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA. evan.scott@northwestern.edu.; Interdisciplinary Biological Sciences Program, Northwestern University, Evanston, IL, USA. evan.scott@northwestern.edu.; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA. evan.scott@northwestern.edu.; Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. evan.scott@northwestern.edu.
المصدر: Nature nanotechnology [Nat Nanotechnol] 2024 May; Vol. 19 (5), pp. 698-704. Date of Electronic Publication: 2024 Jan 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101283273 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1748-3395 (Electronic) Linking ISSN: 17483387 NLM ISO Abbreviation: Nat Nanotechnol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Pub. Group, 2006-
مواضيع طبية MeSH: Mast Cells*/drug effects , Mast Cells*/metabolism , Nanoparticles*/chemistry, Animals ; Mice ; Adsorption ; Humans ; Nanomedicine/methods ; Anaphylaxis ; Polypropylenes/chemistry ; Cell Degranulation/drug effects
مستخلص: Protein adsorption onto nanomaterials often results in denaturation and loss of bioactivity. Controlling the adsorption process to maintain the protein structure and function has potential for a range of applications. Here we report that self-assembled poly(propylene sulfone) (PPSU) nanoparticles support the controlled formation of multicomponent enzyme and antibody coatings and maintain their bioactivity. Simulations indicate that hydrophobic patches on protein surfaces induce a site-specific dipole relaxation of PPSU assemblies to non-covalently anchor the proteins without disrupting the protein hydrogen bonding or structure. As a proof of concept, a nanotherapy employing multiple mast-cell-targeted antibodies for preventing anaphylaxis is demonstrated in a humanized mouse model. PPSU nanoparticles displaying an optimized ratio of co-adsorbed anti-Siglec-6 and anti-FcεRIα antibodies effectively inhibit mast cell activation and degranulation, preventing anaphylaxis. Protein immobilization on PPSU surfaces provides a simple and rapid platform for the development of targeted protein nanomedicines.
(© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
التعليقات: Update of: Res Sq. 2023 Jan 26;:. (PMID: 36747749)
References: Biomaterials. 2019 Oct;219:119357. (PMID: 31351245)
J Clin Invest. 2020 Sep 1;130(9):4759-4770. (PMID: 32484802)
Science. 2018 Mar 16;359(6381):1239-1243. (PMID: 29590071)
Sci Immunol. 2023 Mar 17;8(81):eadc9417. (PMID: 36930731)
J Clin Invest. 2020 Mar 2;130(3):1330-1335. (PMID: 31770111)
Annu Rev Immunol. 2020 Apr 26;38:49-77. (PMID: 32340580)
ACS Cent Sci. 2021 Dec 22;7(12):2063-2072. (PMID: 34963898)
J Allergy Clin Immunol. 2016 Sep;138(3):769-779. (PMID: 27139822)
J Am Chem Soc. 2021 May 19;143(19):7342-7350. (PMID: 33939917)
Nature. 1985 Mar 21-27;314(6008):268-70. (PMID: 2580239)
Methods Mol Biol. 2018;1799:81-92. (PMID: 29956146)
Nat Methods. 2017 Jan;14(1):71-73. (PMID: 27819658)
ACS Nano. 2020 Mar 24;14(3):3563-3575. (PMID: 32053346)
Adv Mater. 2015 Dec 22;27(48):7945-50. (PMID: 26572079)
Nat Rev Immunol. 2014 Oct;14(10):653-66. (PMID: 25234143)
Nat Commun. 2020 Sep 29;11(1):4896. (PMID: 32994414)
Nat Commun. 2021 Jan 28;12(1):648. (PMID: 33510170)
Adv Mater. 2020 Sep;32(37):e2003399. (PMID: 32743864)
J Allergy Clin Immunol. 2021 Jun;147(6):2043-2052. (PMID: 33745886)
J Mol Graph. 1996 Feb;14(1):33-8, 27-8. (PMID: 8744570)
Nat Commun. 2022 Oct 11;13(1):5998. (PMID: 36220817)
J Immunol. 2021 May 15;206(10):2290-2300. (PMID: 33911007)
Chem Soc Rev. 2012 Apr 7;41(7):2780-99. (PMID: 22086677)
Nat Nanotechnol. 2018 Sep;13(9):862-869. (PMID: 29915272)
Nat Nanotechnol. 2016 Apr;11(4):372-7. (PMID: 26878141)
J Control Release. 2007 Jul 16;120(1-2):18-26. (PMID: 17509712)
Adv Colloid Interface Sci. 2011 Feb 17;162(1-2):87-106. (PMID: 21295764)
Cancer Cell. 2022 Mar 14;40(3):255-276. (PMID: 35148814)
Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19274-19281. (PMID: 31501317)
Langmuir. 2010 Nov 16;26(22):16884-9. (PMID: 20942453)
Cells. 2022 Mar 28;11(7):. (PMID: 35406705)
Adv Ther (Weinh). 2021 Aug;4(4):. (PMID: 34485684)
J Immunol. 2004 Dec 1;173(11):6841-9. (PMID: 15557178)
J Allergy Clin Immunol. 2022 Jun;149(6):1866-1874. (PMID: 35421448)
Nat Rev Immunol. 2022 May;22(5):294-308. (PMID: 34611316)
Commun Biol. 2022 Nov 11;5(1):1226. (PMID: 36369358)
Nat Rev Immunol. 2007 Apr;7(4):255-66. (PMID: 17380156)
Nat Mater. 2009 Jul;8(7):543-57. (PMID: 19525947)
J Clin Invest. 2019 Mar 1;129(3):1387-1401. (PMID: 30645205)
معلومات مُعتمدة: U19 AI136443 United States AI NIAID NIH HHS; DMR-0520547 National Science Foundation (NSF); R01 EB030629 United States EB NIBIB NIH HHS; R21 AI159586 United States AI NIAID NIH HHS; R21AI159586 U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID); R01EB030629 U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)
تواريخ الأحداث: Date Created: 20240116 Date Completed: 20240520 Latest Revision: 20240522
رمز التحديث: 20240522
مُعرف محوري في PubMed: PMC11105988
DOI: 10.1038/s41565-023-01584-z
PMID: 38228804
قاعدة البيانات: MEDLINE
الوصف
تدمد:1748-3395
DOI:10.1038/s41565-023-01584-z